Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jardiance vs Renitec in Diabetic Kidney Disease
NCT05373004Phase 3Unknown
- Start
- Mar 2023
- Primary completion
- Mar 2024
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of empagliflozin in diabetic kidney disease (DKD). Status: unknown.
02
Drugs
empagliflozin
03
Conditions
diabetic kidney disease (DKD)
Beyond the preview
Go deeper on NCT05373004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05373004.